Dr. Lal Path Labs Ltd. has informed the Exchange regarding a press release dated April 30, 2026, titled "Press Release on Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2026".
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr Lal PathLabs reported Q4 FY26 revenue of Rs 703 Cr, marking a 16.6% year-on-year growth. EBITDA increased by 10.5% with an EBITDA margin of 26.6%. Profit After Tax (PAT) stood at Rs 132 Cr with a margin of 18.8%. The company announced a final dividend of Rs 4 per share (40%). As of March 31, 2026, the company maintains a strong cash position of Rs 1,526 Cr. The network includes 312 clinical laboratories, 7,727 Patient Service Centers, and 13,935 Pick-up Points across India.
The company delivered solid double-digit revenue and profit growth in Q4 FY26, with healthy margins and a strong cash position. The dividend declaration is positive for shareholders. The results reflect steady operational performance in the diagnostic services sector.